Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine
Etravirine is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretrovirals for treatment-experienced HIV patients ≥6 years of age. Etravirine is primarily metabolized by cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A. This analysis determined the impact of concomitant antiretrovirals and CYP2C9/CYP2C19 phenotype on the pharmacokinetics of etravirine.
We used 4728 plasma concentrations from 817 adult subjects collected from four clinical studies to develop the population pharmacokinetic model. The presence of atazanavir/ritonavir, lopinavir/ritonavir, darunavir/ritonavir, tenofovir disoproxil fumarate, or enfuvirtide together with the CYP2C9 and CYP2C19 phenotype and other demographics were evaluated.
A one-compartment model with first-order input and a lag-time best described the data. Estimates of apparent total clearance (CL/F), apparent central volume of distribution (Vc/F), first-order absorption rate constant (ka), and absorption lag-time were 41.7 L/h, 972 L, 1.16 h, and 1.32 h, respectively. Estimates of between-subject variability on CL/F, Vc/F, and relative bioavailability (F) were 39.4 %CV (percentage coefficient of variation), 35.9 %CV and 35.5 %CV, respectively. Between-occasion variability on F was estimated to be 30.0 %CV. CL/F increased non-linearly with body weight and creatinine clearance (CLCR), and also varied based on CYP2C9/CYP2C19 phenotype.
In this analysis, body weight, CLCR, and CYP2C9/CYP2C19 phenotype were found to describe some of the variability in CL/F. It was not possible to show an impact of concomitant antiretrovirals on the pharmacokinetics of etravirine for adults predominantly taking coadministered boosted protease inhibitors as a background antiretroviral regimen.
- 2.Yanakakis LJ, Bumpus NN. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012;40(4):803–14. doi:10.1124/dmd.111.044404.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob Agents Chemother. 2011;55(5):2290–6. doi:10.1128/AAC.01046-10.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Green B, Holford NH. Critical values for rejecting the null involving mixture models—identification of poor metabolizers and non-responders [poster]. AAPS Annual Meeting; 6–10 Nov 2005; Nashville.Google Scholar
- 21.Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer; 2006.Google Scholar
- 28.Rubner M. Uber den Einfluss der Korpergrosse auf Stoff- und Kraftwechsel. Zeitscrift fur Biol. 1883;19:535–62.Google Scholar
- 34.Orrell C, Felizarta F, Nell A, et al. Pharmacokinetics of etravirine combined with atazanavir/ritonavir and a nucleoside reverse transcriptase inhibitor in antiretroviral treatment-experienced, HIV-1-infected patients. AIDS Res Treat. 2015;2015:938628. doi:10.1155/2015/938628.PubMedPubMedCentralGoogle Scholar
- 35.Arathoon E, Bhorat A, Silaghi R, et al. Week 48 results of a phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults. J Int AIDS Soc. 2014;4(Suppl 3):19783.Google Scholar
- 36.AutoGenomics. INFINITI CYP450 2C19+ assay. http://www.autogenomics.com/?q=node/152. Accessed 12 Sept 2016.
- 37.AutoGenomics. INFINITI CYP450 2C9-VKORC1 assay. http://www.autogenomics.com/?q=node/153. Accessed 12 Sept 2016.